{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:50:31Z","timestamp":1790380231075,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["KLI 1015-B"],"award-info":[{"award-number":["KLI 1015-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.arcmed.2023.102921","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T20:10:48Z","timestamp":1701375048000},"page":"102921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Acromegalic Cardiomyopathy: An Entity on its own? The Effects of GH and IGF-I Excess and Treatment on Cardiovascular Risk Factors"],"prefix":"10.1016","volume":"54","author":[{"given":"Peter","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Maione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5722","authenticated-orcid":false,"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.arcmed.2023.102921_bib0001","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz096","article-title":"A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0002","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape\u00a0: An Update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102921_bib0003","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in Patients with Pituitary Disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102921_bib0005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ando.2020.03.010","article-title":"Cardiovascular complications of acromegaly","volume":"82","author":"Kamenick\u00fd","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2265.2008.03323.x","article-title":"Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly","volume":"70","author":"Boero","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0007","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1210\/jc.2016-1937","article-title":"The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes","volume":"101","author":"Portocarrero-Ortiz","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0008","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1210\/jc.2009-2570","article-title":"Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control","volume":"95","author":"Berg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0009","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1210\/jc.2007-1213","article-title":"Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study","volume":"92","author":"Bogazzi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1530\/EJE-09-0945","article-title":"Acromegaly per se does not increase the risk for coronary artery disease","volume":"162","author":"Akutsu","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0011","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12020-015-0628-4","article-title":"Low risk of coronary artery disease in patients with acromegaly","volume":"50","author":"Dos Santos Silva","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102921_bib0012","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11102-017-0827-5","article-title":"Incidence of myocardial infarction and stroke in acromegaly patients\u00a0: results from the German Acromegaly Registry","volume":"20","author":"Sch\u00f6fl","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102921_bib0013","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General Cardiovascular Risk Profile for Use in Primary Care","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2023.102921_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.02.001","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/EJE-16-0562","article-title":"Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly","volume":"175","author":"Sardella","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0016","first-page":"465","article-title":"Reversible plasma and red blood cells volumes increases in acromegaly","volume":"85","author":"Strauch","year":"1977","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0017","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1172\/JCI102977","article-title":"Body water and sodium in patients with acromegaly","volume":"33","author":"Ikkos","year":"1954","journal-title":"J Clin Invest"},{"key":"10.1016\/j.arcmed.2023.102921_bib0018","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1210\/en.2008-0143","article-title":"Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly","volume":"149","author":"Kamenicky","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.arcmed.2023.102921_bib0019","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1210\/jc.2011-3188","article-title":"Pathophysiology of renal calcium handling in acromegaly: What lies behind hypercalciuria?","volume":"97","author":"Kamenick\u00fd","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/er.2013-1071","article-title":"Growth hormone, insulin-like growth factor-1, and the kidney: Pathophysiological and clinical implications","volume":"35","author":"Kamenick\u00fd","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102921_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1075776","article-title":"Ectopic lipid metabolism in anterior pituitary dysfunction","volume":"14","author":"Baumgartner","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0022","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/jc.2015-1917","article-title":"Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment","volume":"100","author":"Reyes-Vidal","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0023","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1210\/jc.2017-01210","article-title":"Body composition and ectopic lipid changes with biochemical control of acromegaly","volume":"102","author":"Bredella","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-21-0900","article-title":"Treatment of acromegaly has substantial effects on body composition. A long-term follow-up study","volume":"186","author":"Wolf","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102921_bib0026","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41574-019-0280-9","article-title":"The effects of growth hormone on adipose tissue: old observations, new mechanisms","volume":"16","author":"Kopchick","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0027","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fendo.2019.00509","article-title":"Insulin resistance in patients with acromegaly","volume":"10","author":"Vila","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0028","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2337\/diabetes.50.10.2301","article-title":"Pharmacological Antilipolysis Restores Insulin Sensitivity during Growth Hormone Exposure","volume":"50","author":"Nielsen","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.arcmed.2023.102921_bib0029","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","article-title":"Impaired \u03b2-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients","volume":"52","author":"Kasayama","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2021.626427","article-title":"The Interaction of Insulin and Pituitary Hormone Syndromes","volume":"12","author":"Schernthaner-reiter","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0031","first-page":"363","article-title":"Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly","volume":"13","author":"Vilar","year":"2007","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0032","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tem.2016.02.005","article-title":"The Impact of Adipose Tissue on Insulin Resistance in Acromegaly","volume":"27","author":"Olarescu","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0033","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000371818","article-title":"The Metabolic Risk in Patients Newly Diagnosed with Acromegaly Is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment","volume":"103","author":"Olarescu","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102921_bib0034","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archinte.1985.00360050121021","article-title":"Sleep apnea in active acromegaly","volume":"145","author":"Hart","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.arcmed.2023.102921_bib0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-07-0753","article-title":"Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging","volume":"158","author":"van Haute","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0036","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010440","article-title":"Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy","volume":"8","author":"Tietjens","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arcmed.2023.102921_bib0037","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2009-1912","article-title":"Endocrine aspects of obstructive sleep apnea","volume":"95","author":"Attal","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0038","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S2213-2600(12)70051-6","article-title":"Obstructive sleep apnoea and cardiovascular disease","volume":"1","author":"S\u00e1nchez-de-la-Torre","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arcmed.2023.102921_bib0039","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-08-0442","article-title":"Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease","volume":"159","author":"Davi\u2019","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0040","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1210\/jc.2013-4288","article-title":"Impact of successful treatment of acromegaly on overnight heart rate variability and sleep apnea","volume":"99","author":"Chemla","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0041","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1210\/edrv-15-5-555","article-title":"Growth hormone and the heart","volume":"15","author":"Sacc\u00e0","year":"1994","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102921_bib0042","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102921_bib0043","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.2008.03292.x","article-title":"The GH-IGF-I axis and the cardiovascular system: Clinical implications","volume":"69","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0044","first-page":"1086","article-title":"American Society of Echocardiography recommendations for use of echocardiography in clinical trials","volume":"17","author":"Gottdiener","year":"2004","journal-title":"J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr"},{"key":"10.1016\/j.arcmed.2023.102921_bib0045","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2015-2675","article-title":"Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort","volume":"100","author":"Dos Santos Silva","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0046","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ejendo\/lvad105","article-title":"Increase in intracellular and extracellular myocardial mass in patients with acromegaly: a cardiac magnetic resonance imaging study","volume":"189","author":"Wolf","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0047","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1056\/NEJM199910213411706","article-title":"Signaling pathways for cardiac hypertrophy and failure","volume":"341","author":"Hunter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2023.102921_bib0048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(80)90277-X","article-title":"Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients","volume":"100","author":"Lie","year":"1980","journal-title":"Am Heart J"},{"key":"10.1016\/j.arcmed.2023.102921_bib0049","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1073\/pnas.91.5.1686","article-title":"Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes","volume":"91","author":"Donath","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2023.102921_bib0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/01.RES.83.1.50","article-title":"Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles","volume":"83","author":"Cittadini","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.arcmed.2023.102921_bib0051","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1210\/jc.2011-0078","article-title":"Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0052","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2214\/AJR.07.2031","article-title":"Rapidly Reversible Myocardial Edema in Patients with Acromegaly\u00a0: Assessment with Ultrafast T2 Mapping in a Single- Breath-Hold","volume":"190","author":"Gouya","year":"2008","journal-title":"AJR"},{"key":"10.1016\/j.arcmed.2023.102921_bib0053","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EC-17-0031","volume":"6","author":"Wolf","year":"2017","journal-title":"lipids and hormones. Endocr Connect"},{"key":"10.1016\/j.arcmed.2023.102921_bib0054","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1210\/jc.2014-2242","article-title":"No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy","volume":"99","author":"Winhofer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1172\/JCI114737","article-title":"Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle","volume":"86","author":"Timsit","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.arcmed.2023.102921_bib0056","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1210\/jc.2004-0821","article-title":"Long-term outcome of patients with acromegaly and congestive heart failure","volume":"89","author":"Bihan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0057","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0058","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2002.01528.x","article-title":"Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy","volume":"56","author":"Herrmann","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0059","first-page":"196","article-title":"Impaired left ventricular diastolic filling in patients with acromegaly: assessment with radionuclide angiography","volume":"36","author":"Cuocolo","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.arcmed.2023.102921_bib0060","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1210\/jc.2003-030462","article-title":"Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly","volume":"88","author":"Spinelli","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0061","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1210\/jc.2002-021099","article-title":"High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study","volume":"88","author":"Colao","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0062","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1210\/jc.2003-030849","article-title":"Increased prevalence of regurgitant valvular heart disease in acromegaly","volume":"89","author":"Pereira","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0063","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","article-title":"Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0064","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","article-title":"Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia","volume":"95","author":"Valassi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/jc.2013-2254","article-title":"A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists","volume":"99","author":"Drake","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0066","doi-asserted-by":"crossref","first-page":"E1714","DOI":"10.1210\/jc.2012-1833","article-title":"No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly","volume":"97","author":"Maione","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0067","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehab822","article-title":"Acromegaly and cardiovascular outcomes\u00a0: a cohort study","volume":"43","author":"Hong","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arcmed.2023.102921_bib0068","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11102-016-0749-7","article-title":"Low frequency of cardiac arrhythmias and lack of structural heart disease in medically-na\u00efve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment","volume":"19","author":"Warszawski","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102921_bib0069","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11102-014-0605-6","article-title":"Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues","volume":"18","author":"Comunello","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102921_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40618-020-01343-0","article-title":"Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?","volume":"44","author":"Parolin","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102921_bib0071","first-page":"1551","article-title":"Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0072","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2265.2001.01343.x","article-title":"Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients","volume":"55","author":"Minniti","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0073","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis","volume":"92","author":"Maison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0074","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1530\/EJE-15-0500","article-title":"Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study","volume":"173","author":"Kuhn","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jc.2006-1587","article-title":"Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance","volume":"92","author":"Pivonello","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0076","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of Somatostatin Analogs on the Heart in Acromegaly\u00a0: A Metaanalysis","volume":"92","author":"Maison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0077","doi-asserted-by":"crossref","first-page":"921","DOI":"10.7326\/0003-4819-113-12-921","article-title":"Cardiovascular effects of the somatostatin analog octreotide in acromegaly","volume":"113","author":"Chanson","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arcmed.2023.102921_bib0078","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2169\/internalmedicine.49.3972","article-title":"A case of juvenile acromegaly that was initially diagnosed as severe congestive heart failure from acromegaly-induced dilated cardiomyopathy","volume":"49","author":"Sue","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.arcmed.2023.102921_bib0079","doi-asserted-by":"crossref","first-page":"987","DOI":"10.4103\/2230-8210.103007","article-title":"Congestive heart failure in acromegaly: A review of 6 cases","volume":"16","author":"Dutta","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0080","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12020-018-1797-8","article-title":"Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bic\u00eatre cohort, and review of the literature","volume":"63","author":"Briet","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102921_bib0081","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/cen.12455","article-title":"The beneficial effect of acromegaly control on blood pressure values in normotensive patients","volume":"81","author":"Sardella","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0082","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1210\/jc.2018-00325","article-title":"Persistence of Diabetes and Hypertension After Multimodal Treatment of Acromegaly","volume":"103","author":"Gonzalez","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0083","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1210\/jc.2014-2259","article-title":"Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk","volume":"99","author":"Reyes-Vidal","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0084","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/eje.0.1480193","article-title":"Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly","volume":"148","author":"Jaffrain-Rea","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0085","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0086","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","article-title":"Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors","volume":"91","author":"Ronchi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0087","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12020-016-0995-5","article-title":"Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly","volume":"55","author":"Auriemma","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102921_bib0088","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","article-title":"Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: A study in 148 patients","volume":"17","author":"Alexopoulou","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102921_bib0089","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/EJE-10-1096","article-title":"Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic \u03b2-cell function is preserved","volume":"164","author":"Kinoshita","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0090","first-page":"1012","article-title":"Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy","volume":"74","author":"M\u00f8ller","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0091","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","article-title":"Diabetes in patients with acromegaly treated with pegvisomant\u00a0: observations from acrostudy","volume":"63","author":"Brue","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102921_bib0092","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose Homeostasis and Safety in Patients with Acromegaly Converted from Long-Acting Octreotide to Pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0093","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1210\/jc.2006-2276","article-title":"The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly","volume":"92","author":"Lindberg-Larsen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0094","first-page":"372","article-title":"Bromocritpine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion","volume":"72","author":"Rau","year":"1993","journal-title":"Clin Investig"},{"key":"10.1016\/j.arcmed.2023.102921_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00358","article-title":"Diabetes Secondary to Acromegaly\u00a0: Physiopathology, Clinical Features and Effects of Treatment","volume":"9","author":"Ferra\u00f9","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0096","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1210\/jc.2008-2627","article-title":"Glucose tolerance and somatostatin analog treatment in acromegaly: A 12-month study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0097","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.2165\/00003495-200868050-00014","article-title":"Lanreotide Autogel\u00ae in the Management of Acromegaly","volume":"68","author":"Molitch","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.arcmed.2023.102921_bib0098","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11102-017-0821-y","article-title":"A multicenter, observational study of lanreotide depot \/autogel (LAN) in patients with acromegaly in the United States\u00a0: 2-year experience from the SODA registry","volume":"20","author":"Salvatori","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102921_bib0099","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0100","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0296","article-title":"Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR","volume":"11","author":"Wolf","year":"2022","journal-title":"Endocr Connect"},{"key":"10.1016\/j.arcmed.2023.102921_bib0101","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.arcmed.2023.102921_bib0102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12020-023-03352-4","article-title":"How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients","volume":"80","author":"Zaina","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102921_bib0103","first-page":"1","article-title":"Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition","author":"Wolf","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arcmed.2023.102921_bib0104","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMc1915808","article-title":"Eucaloric Very-Low-Carbohydrate Ketogenic Diet in Acromegaly Treatment","volume":"382","author":"Coopmans","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2023.102921_bib0105","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1210\/jc.2017-00082","article-title":"Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly","volume":"102","author":"Quarella","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102921_bib0106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12020-021-02718-w","article-title":"Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review","volume":"73","author":"Zaina","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102921_bib0107","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.arcmed.2023.102921_bib0108","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40618-015-0404-6","article-title":"Italian Society for the Study of Diabetes (SID)\/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing \u2019 s syndrome and acromegaly","volume":"39","author":"Giorgino","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102921_bib0109","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/EJE-20-0497","article-title":"Metabolic complications in acromegaly after neurosurgery\u00a0: a meta-analysis","volume":"183","author":"Cozzolino","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102921_bib0110","doi-asserted-by":"crossref","unstructured":"Shao X, Chen Z, Wang M, et\u00a0al. Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120 Cases 2022;54:25\u201332. doi: 10.1055\/a-1717-9332.","DOI":"10.1055\/a-1717-9332"},{"key":"10.1016\/j.arcmed.2023.102921_bib0111","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eem.11.82","article-title":"Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment","volume":"7","author":"Dav\u00ec","year":"2012","journal-title":"Expert Rev Endocrinol Metab"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:15:14Z","timestamp":1741184114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440923001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":111,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0188440923001595"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102921","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acromegalic Cardiomyopathy: An Entity on its own? The Effects of GH and IGF-I Excess and Treatment on Cardiovascular Risk Factors","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102921"}}